Is COVID-19 A Preexisting Condition For Which Americans Could Lose Coverage? Some Senators Say So

Other senators at hearing call CDC advice unclear on if asymptomatic people with close contacts to those infected should get testing

US Senators said Wednesday coronavirus patients could lose coverage if the ACA is abolished by a new Supreme Court, while Sen. Warren accused a COVID-19 response advisor of conflicts of interest.

Legislators on 23 September asked several Trump administration officials if infection with COVID-19 can be considered a preexisting condition that would be no longer coverable if the Affordable Care Act is struck down by a more conservative Supreme Court, and if asymptomatic people should be tested for the virus, or not.

The lawmakers spoke at a Senate Health, Education, Labor and Pensions (HELP) Committee hearing on progress in fighting the COVID-19...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Policy & Regulation

European Medtechs Reiterate Opposition To Reciprocal Tariffs On US Imports

 
• By 

EU countermeasures against US tariffs suggest medtech categories exported to the EU could be targeted for tariffs. MedTech Europe and the German IVDs industry have stressed the negative effects this would have on patient care.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By 

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

MHRA’s Tallon Hails PMS Regulation As Start Of UK Device Framework Transformation

 
• By 

16 June marked the first major new regulatory instrument in the UK’s post-Brexit transition to a standalone device regulatory system for Great Britain.